Skip to content
Screener

Syndax Pharmaceuticals SNDX EBITDA margin

Discontinued — last reported Q4 '19

EBITDA margin at other companies

Biogen logo
BiogenBIIB
21.2%-6.1pp
Incyte logo
IncyteINCY
32.2%+4.5pp
Kura Oncology logo
Kura OncologyKURA
-441.9%+103pp
AbbVie logo
AbbVieABBV
37.3%—
Nuvation Bio logo
Nuvation BioNUVB
-79.7%-38.8pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-569%-284pp

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.76B+58.9%
Enterprise value$1.98B+48.9%
P/S8.1×-6.1×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Calculated from Syndax Pharmaceuticals’s reported figures.

ebitda/total revenue=-3,829.7%

Based on trailing twelve months.

The source filing: Syndax Pharmaceuticals’s 10-K, filed March 1, 2022. Open the filing →

Filed
Mar 1, 2022, 5:23 PM EST
Fiscal year
FY2021
Accession
0001564590-22-008112

FAQ

What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.